Question · asked by 1 review

Eculizumab vs placebo: Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months

It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Eculizumab vs placebo
Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane Headline outcomes only
RR 1.21 [0.15, 10.11]2 studies · 38 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome
2020 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.